| Ms Oluyemisi Olayinka Adedotun, APRN | |
|
3430 E Flamingo Rd Ste 100, Las Vegas, NV 89121-5018 | |
| (702) 444-4690 | |
| (702) 444-0977 |
| Full Name | Ms Oluyemisi Olayinka Adedotun |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 15 Years |
| Location | 3430 E Flamingo Rd Ste 100, Las Vegas, Nevada |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629393632 | NPI | - | NPPES |
| APN001368 | Other | NV | NV LICENSE |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Psychiatric Solutions Clinic | 9931508280 | 3 |
News Archive
Why do we almost instinctively treat babies as special, protecting them and enabling them to survive? Darwin originally pointed out that there is something about infants which prompts adults to respond to and care for them which allows our species to survive.
ISTA Pharmaceuticals, Inc., today announced the Company's supplemental New Drug Application (sNDA) for once-daily XiDay™ (bromfenac ophthalmic solution) has been accepted for review by the U.S. Food and Drug Administration (FDA).
Multiple data sources, including scientific survey data, medical studies and analyses of data in regions that have imposed ambulance fees, indicate that ambulance fees will discourage calls to emergency services for help, risking the health and safety of those experiencing medical emergencies.
Researchers report a dose–response relationship between body mass index and cardiovascular risk even in severely obese adolescents, making its assessment important to limit further disease progression.
Senesco Technologies, Inc. today announced that preclinical data for the Company's lead drug candidate, SNS-01, will be presented on May 20, 2010 at the American Society of Gene and Cell Therapy Annual Meeting being held at the Marriott Wardman Park Hotel in Washington, D.C. from May 17 to 22.
› Verified 1 days ago
| Entity Name | Rf Ramirez Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386072957 PECOS PAC ID: 9638309107 Enrollment ID: O20140228000838 |
News Archive
Why do we almost instinctively treat babies as special, protecting them and enabling them to survive? Darwin originally pointed out that there is something about infants which prompts adults to respond to and care for them which allows our species to survive.
ISTA Pharmaceuticals, Inc., today announced the Company's supplemental New Drug Application (sNDA) for once-daily XiDay™ (bromfenac ophthalmic solution) has been accepted for review by the U.S. Food and Drug Administration (FDA).
Multiple data sources, including scientific survey data, medical studies and analyses of data in regions that have imposed ambulance fees, indicate that ambulance fees will discourage calls to emergency services for help, risking the health and safety of those experiencing medical emergencies.
Researchers report a dose–response relationship between body mass index and cardiovascular risk even in severely obese adolescents, making its assessment important to limit further disease progression.
Senesco Technologies, Inc. today announced that preclinical data for the Company's lead drug candidate, SNS-01, will be presented on May 20, 2010 at the American Society of Gene and Cell Therapy Annual Meeting being held at the Marriott Wardman Park Hotel in Washington, D.C. from May 17 to 22.
› Verified 1 days ago
| Entity Name | Psychiatric Solutions Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780059352 PECOS PAC ID: 9931508280 Enrollment ID: O20210519000700 |
News Archive
Why do we almost instinctively treat babies as special, protecting them and enabling them to survive? Darwin originally pointed out that there is something about infants which prompts adults to respond to and care for them which allows our species to survive.
ISTA Pharmaceuticals, Inc., today announced the Company's supplemental New Drug Application (sNDA) for once-daily XiDay™ (bromfenac ophthalmic solution) has been accepted for review by the U.S. Food and Drug Administration (FDA).
Multiple data sources, including scientific survey data, medical studies and analyses of data in regions that have imposed ambulance fees, indicate that ambulance fees will discourage calls to emergency services for help, risking the health and safety of those experiencing medical emergencies.
Researchers report a dose–response relationship between body mass index and cardiovascular risk even in severely obese adolescents, making its assessment important to limit further disease progression.
Senesco Technologies, Inc. today announced that preclinical data for the Company's lead drug candidate, SNS-01, will be presented on May 20, 2010 at the American Society of Gene and Cell Therapy Annual Meeting being held at the Marriott Wardman Park Hotel in Washington, D.C. from May 17 to 22.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Oluyemisi Olayinka Adedotun, APRN 3430 E Flamingo Rd Ste 100, Las Vegas, NV 89121-5018 Ph: (702) 444-4690 | Ms Oluyemisi Olayinka Adedotun, APRN 3430 E Flamingo Rd Ste 100, Las Vegas, NV 89121-5018 Ph: (702) 444-4690 |
News Archive
Why do we almost instinctively treat babies as special, protecting them and enabling them to survive? Darwin originally pointed out that there is something about infants which prompts adults to respond to and care for them which allows our species to survive.
ISTA Pharmaceuticals, Inc., today announced the Company's supplemental New Drug Application (sNDA) for once-daily XiDay™ (bromfenac ophthalmic solution) has been accepted for review by the U.S. Food and Drug Administration (FDA).
Multiple data sources, including scientific survey data, medical studies and analyses of data in regions that have imposed ambulance fees, indicate that ambulance fees will discourage calls to emergency services for help, risking the health and safety of those experiencing medical emergencies.
Researchers report a dose–response relationship between body mass index and cardiovascular risk even in severely obese adolescents, making its assessment important to limit further disease progression.
Senesco Technologies, Inc. today announced that preclinical data for the Company's lead drug candidate, SNS-01, will be presented on May 20, 2010 at the American Society of Gene and Cell Therapy Annual Meeting being held at the Marriott Wardman Park Hotel in Washington, D.C. from May 17 to 22.
› Verified 1 days ago
Dena Kae Meeter, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 7455 W Washington Ave, #160, Las Vegas, NV 89128 Phone: 702-878-0393 Fax: 702-940-5601 | |
Ms. Lotis Gay Perilla Edano, APRN, NP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2545 S Bruce St Ste 200, Las Vegas, NV 89169 Phone: 702-732-2438 Fax: 702-733-7876 | |
Jann Stacey Pickens, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 620 Shadow Ln, Las Vegas, NV 89106 Phone: 702-388-4506 Fax: 702-388-4810 | |
Tamaris Samantha Cotta, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 9280 W Sunset Rd Ste 400, Las Vegas, NV 89148 Phone: 702-366-1268 Fax: 702-366-7079 | |
Tasha Gouin, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 9097 W Post Rd Ste 100, Las Vegas, NV 89148 Phone: 702-430-5333 | |
Aric Pedro Adaoag, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 9816 Gilespie St Ste 550, Las Vegas, NV 89183 Phone: 702-202-6336 Fax: 702-202-6318 | |
Ms. Michele Marie Brock, NURSE PRACTITIONER Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 5380 S Rainbow Blvd Ste 120, Las Vegas, NV 89118 Phone: 702-463-4040 |